Topics covered include:

• Introduction
• HIV Nucleoside Analogue Reverse Transcriptase Inhibitors
• HIV Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)
• HIV Protease Inhibitors
• HIV Entry Inhibitors

Learning Objectives

Upon completion of this activity, participants should be able to:

• List new classes of antiretrovirals with different mechanisms of action from existing classes

• Identify new antiretrovirals in existing classes that may provide benefit to treatment-experienced patients

• Describe the current drug development status of selected investigational antiretrovirals

Topics covered include:

• Introduction
• Interpreting Studies of Salvage Regimens
• Recent Data on Boosted-PI Regimens
• Recent Data on Boosted-PI Regimens (Continued)
• Use of a New Class in Treatment-Experienced Patients

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review important considerations in the interpretation of studies of salvage regimens

• Discuss recent data on the use of boosted protease inhibitor regimens in treatment-experienced patients

• Describe the results of studies in which a new antiretroviral class was used in salvage regimens

Topics covered include:

• Introduction
• Patient-Related Factors
• Patient-Related Factors (Continued)
• Treatment-Related Factors
• Treatment-Related Factors (Continued)

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the role of resistance testing in guiding the selection of effective regimens for treatment-experienced patients

• Review the outcomes of studies of treatment interruptions before initiation of a salvage regimen

• Discuss the importance of establishing a therapeutic partnership with patients to maximize the likelihood of good adherence

Topics covered include:

• Introduction
• Viral Fitness, Replication Capacity, and Virulence
• Defining Treatment Failure
• Discordant Virologic and Immunologic Responses
• Guidelines for Drug Resistance Testing

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe recent insights into reduced susceptibility to enfuvirtide

• Review current understanding of the reasons for discordant immunologic and virologic responses

• Discuss appropriate definitions of treatment failure and related concepts including viral fitness and replication capacity

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe the impact of resistance mutations on response to subsequent antiretroviral regimens

• Discuss the optimal use of enfuvirtide in treatment-experienced patients

• Review the strategy of using double-boosted PIs in treatment-experienced patients

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review data on the safety and efficacy of enfuvirtide in treatment-experienced patients

• Describe the appropriate management of treatment-related toxicities in the salvage setting

• Discuss the utility of resistance testing in treatment-experienced patients